Leo Reap, DO
Internal Medicine · Bingham Farms, MINPI 1568844082
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,980 of the $4,326 with a category attached, or 68.9%. 30 manufacturers reported payments, led by Novartis at 31.1% of the total. 2025 is the largest year on record at $1,575, 2.0 times the $782 reported in 2019. Among internal medicine clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 123 payments — averaging $35.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Gilead$971
- Genentech USA, Inc.$370
- Johnson & Johnson$295
- E.r. Squibb & Sons, L.L.C.$259
- AbbVie$192
- plus $892 from 24 others
Across 45 payments — averaging $4531.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$204K
What the payments were for
- Food & beverage$2,98069%
- Education$64815%
- Other$69816%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 24 | $1,347 |
| Gilead(2 entities) | 27 | $971 |
| Genentech USA, Inc. | 6 | $370 |
| Johnson & Johnson(2 entities) | 5 | $295 |
| E.r. Squibb & Sons, L.L.C. | 16 | $259 |
| AbbVie | 7 | $192 |
| Incyte Corporation | 1 | $125 |
| Astellas Pharma US Inc | 2 | $114 |
| Eisai Inc. | 3 | $63 |
| Amgen | 4 | $63 |
| Bristol Myers Squibb | 3 | $63 |
| EMD Serono, Inc. | 2 | $42 |
| AVEO Pharmaceuticals, Inc. | 2 | $34 |
| Ipsen Biopharmaceuticals, Inc | 2 | $34 |
| GSK | 2 | $33 |
| Tersera Therapeutics LLC | 2 | $32 |
| Recordati_rare_diseases_inc. | 1 | $32 |
| Merck | 2 | $30 |
| Genmab U.S., Inc. | 1 | $28 |
| Pfizer | 1 | $23 |
| Agios Pharmaceuticals, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $20 |
| Tempus AI, Inc | 1 | $20 |
| Taiho Oncology, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Array Biopharma Inc | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Sobi, Inc | 1 | $17 |
| Puma Biotechnology, Inc. | 1 | $14 |
| Sanofi | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,326 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 62 | $880,310 |
| Lenalidomide | 58 | $799,597 |
| RevlimidLenalidomide | 23 | $501,169 |
| IbrancePalbociclib | 21 | $327,479 |
| ImbruvicaIbrutinib | 23 | $271,895 |
| SprycelDasatinib | 19 | $263,369 |
| PomalystPomalidomide | 12 | $244,831 |
| NubeqaDarolutamide | 14 | $181,974 |
| NinlaroIxazomib Citrate | 11 | $144,931 |
| TasignaNilotinib Hcl | 12 | $116,892 |
| EliquisApixaban | 73 | $87,670 |
| XareltoRivaroxaban | 18 | $27,500 |
| Anastrozole | 168 | $6,428 |
| OxycontinOxycodone Hcl | 12 | $5,052 |
| Hydroxyurea | 87 | $5,021 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Sprycel, Pomalyst | $259 | $508,20131 claims |
| Bristol Myers SquibbRevlimid | $63 | $501,16923 claims |
| PfizerIbrance, Eliquis | $23 | $415,15094 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $18 | $144,93111 claims |
| NovartisTasigna | $1,347 | $116,89212 claims |
| Johnson & JohnsonXarelto | $295 | $27,50018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Bingham Farms
- Terry SmithAnn Arbor$2.3M
- Michael ValituttoKalamazoo$1.8M
- Ulka VaishampayanAnn Arbor$996K
- Tina AbrahamPontiac$834K
- Steven KatzmanLivonia$715K
- Adam FormanSouthfield$453K
- Saroj NeupaneDetroit$373K
- James BazziDearborn Heights$368K
- Mohamad HatahetWaterford$352K
- A FendrickAnn Arbor$347K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.